Acute Lymphoblastic Leukemia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Determining the Mechanisms of Loss of CAR T Cell Persistence
Conditions: Acute Lymphoblastic Leukemia With Failed Remission; Acute Lymphoblastic Leukemia Not Having Achieved Remission; Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, in Relapse Intervention: Sponsor: University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
Conditions: Allogeneic Hematopoietic Stem Cell Transplantation; Acute Lymphoblastic Leukemia Intervention: Drug: VEN+AZA+Modified BUCY Sponsor: The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2023 Category: Research Source Type: clinical trials

Anti-mullerian Hormone in Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia Intervention: Sponsor: IRCCS Burlo Garofolo Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2023 Category: Research Source Type: clinical trials

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Conditions: Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin's Lymphoma, Relapsed; Non-Hodgkin's Lymphoma Refractory; Acute Lymphoblastic Leukemia With Failed Remission; B-cell Non Hodgkin Lymphoma; B Cell Leukemia Intervention: Biological: CD19 specific Chimeric Antigen Receptor T Cell Sponsor: Nationwide Children's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2023 Category: Research Source Type: clinical trials